Company intelligence / Profile preview

Holles Laboratories, Inc.

Cohasset, Massachusetts, United Statesaccessdata.fda.gov ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Holles Laboratories developed Dehydrex, a topical treatment evaluated in a compassionate-use clinical trial for recurrent corneal erosion. The highest phase reached is "Pending," with at least one completed study but no reported regulatory approvals as of the latest update.

Therapeutic areas: Ophthalmology
Modalities: Large molecular weight fluorescent solutions (for contact lenses)Small molecule drug (Dehydrex)
Industry: Biotech

Drug pipeline

1 asset

dextran 70

Pre-clinical

Indications: Recurrent corneal erosion

Beyond the preview

Go deeper on Holles Laboratories, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Holles Laboratories, Inc..

Explore the full profile